Vaxcell-Bio Therapeutics, a South Korean company specializing in anti-cancer immunotherapy, announced on Wednesday its partnership with Cellid Co. to develop an advanced cancer immunotherapy platform.
Vaxcell-Bio is dedicated to researching and developing various types of cancer treatments using the anti-cancer immunotherapy platform. To expedite the development of next-generation anti-cancer immunotherapy drugs, Vaxcell-Bio signed an agreement with Cellid the previous day.
Chimeric antigen receptor (CAR) treatment, the next generation of anti-cancer immunotherapy, is referred to as the "dream anti-cancer drug" because it offers long-term patient survival with a single administration. However, as CAR treatments involve multiple rounds of genetic manipulation, the R&D process requires significant time and resources. Currently, only six CAR treatments have been approved worldwide, all targeting hematologic malignancies.
Vaxcell-Bio has been focused on developing CAR treatments for an extended period and has recently produced meaningful results in the R&D phase. The company aims to commence clinical studies shortly.
"Our company is currently making a concerted effort by restructuring our organization and recruiting doctoral-level researchers," stated Lee Je-jung, CEO of Vaxcell-Bio. "We plan to collaborate actively with other companies, such as consignment production of the lentivirus, to become a leader in the development of CAR treatments."
"Through this latest agreement, we expect to contribute to creating positive economic effects and accelerating the growth of the cutting-edge biomedicine industry by addressing the issues of development speed and cost that have hindered many bio companies from advancing," added Kang Chang-yuil, CEO of Cellid.
We use cookies to provide the best user experience. By continuing to browse this website, you will be considered to accept cookies. Please review our Privacy Policy to learn our cookie policy.